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Objective. This retrospective cohort study evaluated the effects of whole body therapeutic hypothermia (WBTH) on gastrointestinal
(GI) morbidity and feeding tolerance in infants with moderate-to-severe hypoxic ischemic encephalopathy (HIE). Study Design.
Infants ≥ 35 weeks gestational age and ≥1800 grams birth weight with moderate-to-severe HIE treated from 2000 to 2012 were
compared. 68 patients had documented strictly defined criteria for WBTH: 32 historical control patients did not receive WBTH
(non-WBTH) and 36 cohort patients received WBTH. Result. More of the non-WBTH group infants never initiated enteral feeds
(28% versus 6%; 𝑃 = 0.02), never reached full enteral feeds (38% versus 6%, 𝑃 = 0.002), and never reached full oral feeds (56%
versus 19%, 𝑃 = 0.002). Survival analyses demonstrated that the WBTH group reached full enteral feeds (median time: 11 versus 9
days; 𝑃 = 0.02) and full oral feeds (median time: 19 versus 10 days; 𝑃 = 0.01) sooner. The non-WBTH group had higher combined
outcomes of death and gastric tube placement (47% versus 11%; 𝑃 = 0.001) and death and gavage feeds at discharge (44% versus
11%; 𝑃 = 0.005). Conclusion. WBTH may have beneficial effects on GI morbidity and feeding tolerance for infants with moderateto-severe HIE.

1. Introduction
Perinatal HIE is associated with high morbidity and mortality
in the neonatal period as well as long-term neurocognitive
deficits. Although slightly different inclusion criteria were
used among studies, multiple randomized controlled trials demonstrate that WBTH has a statistically significant
improvement in neurodevelopmental disability at 18 to 24
months of [1–3] followup and 6 to 7 years of followup [4] for
infants with moderate-to-severe HIE at birth. However, the
effects of a perinatal hypoxic ischemic event extend beyond
the brain and neurodevelopment. Decreased perfusion to
the GI tract [5] and decreased motility leading to feeding
intolerance [6] may follow perinatal asphyxia. Patients can
present with symptoms of GI bleeding, vomiting, diarrhea,

and even necrotizing enterocolitis (NEC) following HIE
[7, 8]. Since WBTH acts to prevent secondary damage to
the brain from ischemia and reperfusion injury that occurs
following periods of perinatal anoxia, it is plausible to believe
that WBTH could have similar preventative effects on the
ischemic damage to the GI system.
Previous studies demonstrate conflicting results. There
were some indications of hepatic dysfunction and feeding
disturbances seen in subjects involved in a few of the major
studies for therapeutic hypothermia, but none of those
studies focused specifically on the effects to the GI system
as a primary outcome. For example, the Cool Cap study,
using selective head cooling, reported elevated liver enzymes
(aspartate transaminase > 200 IU/L and alanine transaminase
> 100 IU/L) in 38% of the cooled subjects versus 53% of
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controls (𝑃 = 0.02) [9]. Another selective head cooling trial,
performed by Zhou et al., reported raised liver enzymes (not
defined) in 35% of the cooled subjects versus 28% of the
controls (𝑃 > 0.05) [10]. The ICE study reported 35% of subjects who received WBTH with hepatic dysfunction (alanine
aminotransferase level > 100 U/L) versus 45% of controls
(𝑃 > 0.05). This study also found a higher incidence of
GI impairment (sloughing of the bowel, rectal bleeding,
or NEC) in 4% of cooled subjects versus 2% of controls
(𝑃 > 0.05) [2]. Another WBTH study, sponsored by the
National Institute of Child Health and Human Development
(NICHD), reported hepatic dysfunction (aspartate aminotransferase level > 200 IU and alanine aminotransferase level
> 100 IU) in 20% of cooled subjects versus 15% of controls
(significance not reported but calculated 𝑃 > 0.05). In the
cooled group, 11% of patients were discharged on gavage
feeds versus 7% of controls (significance not reported but
calculated 𝑃 > 0.05) and 7% of patients were discharged with
a gastric tube (GT) versus 17% of controls (significance not
reported but calculated 𝑃 > 0.05) [3]. Finally, the TOBY trial
for WBTH reported only one case of NEC in a cooled patient
and no cases of NEC in the control group (<1% versus 0%, no
significance) [1].
To our knowledge, there are no published clinical trials
evaluating the effects of therapeutic hypothermia for GI
ischemia and reperfusion injury following HIE in humans,
but several animal studies suggest a benefit. Pierro and Eaton
[11] developed a rat model of intestinal ischemia-reperfusion
by surgically isolating and temporarily occluding the superior
mesenteric artery for 30-minute duration and then assessing
signs of metabolic and histologic damage incurred to the
GI tract after 60 minutes of reperfusion. They demonstrated
evidence of liver energy failure, intestinal damage, and 100%
mortality in the animals within 4 hours of reperfusion at
normothermia. However, when the rats were kept hypothermic (32-33∘ C) by controlling the environmental temperature,
there was a significant decrease in metabolic and histologic
damage as well as 100% survival [11]. Hassoun et al. used a
similar rat model with 45 minutes of induced ischemia and
6 hours of reperfusion to demonstrate decreased levels of
inflammatory markers (nuclear factor kappa-B and inducible
nitric oxide synthase); an increased level of a protective
marker (heme oxygenase-1) and decreased histologic intestinal damage after direct hypothermia was applied to the
GI tract during the ischemic period [12]. Finally, Stefanutti
and colleagues [13] used the same rat model with “rescue”
hypothermia applied by controlling the environmental temperature only during the reperfusion period. After 60 minutes
of ischemia and 2 to 5 hours of reperfusion, hypothermia led
to 100% survival and reduced inflammation, metabolic injury,
and histologic damage to the GI tract [13].
We wanted to apply this evidence for WBTH use in
animal models with ischemia-reperfusion injury to clinical
practice. The purpose of our study was to evaluate the
effects of WBTH on GI function and feeding tolerance in
infants diagnosed with moderate-to-severe HIE. The primary
objective was to determine the number of days to reach
full enteral feeds and to reach full oral feeds in a group of
infants with HIE treated with WBTH compared to a historical
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control group of infants with HIE prior to the routine use
of WBTH. Our hypothesis was that WBTH would have a
protective effect on GI function and feeding tolerance status
post-moderate-to-severe HIE.

2. Methods
2.1. Study Population: Total. Study approval was obtained
from the Institutional Review Board of Children’s Mercy
Hospitals (Kansas City, MO). There were 435 total patients
identified for retrospective analysis: 347 in the non-WBTH
group and 88 in the WBTH group. 287 total patients were
excluded from the study because they did not meet criteria
for moderate-to-severe HIE, because they had a significant
congenital defect at birth, because they were enrolled in
another research study involving WBTH, or because there
was insufficient data available in the medical record. There
were 78 patients in the non-WBTH general criteria (defined
below) group and 70 patients in the WBTH general criteria
group. There were 32 patients in the non-WBTH strict criteria
(defined below) group and 36 patients in the WBTH strict
criteria group (Figure 1).
2.2. Study Population: Non-WBTH Group. Medical charts
were reviewed for all infants ≥ 35 weeks of gestational
age and ≥ 1800 grams of birth weight admitted to our
institution from January 2000 to December 2008 with at
least one of the following diagnoses on admission: hypoxic
ischemic encephalopathy, birth asphyxia, meconium aspiration, nuchal cord, placental abruption, seizure, depression
at birth, acidosis at birth, and/or shoulder dystocia. Strict
criteria for the use of WBTH at our institution are based on
previously published data [1–3, 9, 10, 14] and defined as a
history of birth asphyxia, severe metabolic acidosis on cord
blood gases or blood gas obtained within 1 hour of life (pH
≤ 7 or base deficit ≥ 16 or pH 7.01–7.15 or base deficit 10–16
and 10-minute APGAR score ≤ 5 or assisted ventilation at
birth continued ≥ 10 minutes), and seizures or other evidence
of moderate-to-severe encephalopathy (decreased consciousness, decreased-to-no activity, distal flexion or decerebrate
posturing, hypotonia, decreased or absent reflexes, abnormal pupillary response, and abnormal breathing pattern) as
documented in the medical record. Patients with adequate
documentation were included in the study as historical
controls and defined as the non-WBTH strict criteria group.
When data for these criteria was missing, the record was
reviewed further to identify other evidence of significant
HIE. If patients had indirect evidence of moderate-to-severe
HIE (abnormal lab values, abnormal neuroimaging, death,
etc.), they were included as historical controls in the larger
non-WBTH general criteria group. If the degree of HIE was
considered to be mild or insufficient evidence was ultimately
found to determine HIE status, the patient was excluded from
the analysis. Patients with significant congenital anomalies
at birth (congenital heart disease, gastroschisis, omphalocele,
intestinal atresia, chromosomal trisomy, hydrocephalus, etc.)
or patients involved in another study protocol using WBTH
were also excluded.
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5 missing data

Figure 1: Study population.

2.3. Study Population: WBTH Group. A data set had been
previously collected for quality purposes on all patients
receiving WBTH from the start of standard practice use at our
institution in December 2008 up to December 2012. These
patients had been diagnosed with moderate-to-severe HIE
based on the aforementioned criteria and completed 72 hours
of WBTH at 33-34∘ C. In some instances, inadequate documentation existed so that all of the criteria were not found
for each patient. The WBTH strict criteria group included
only those patients with all criteria clearly documented, while
the WBTH general criteria group included all patients who
received WBTH. Again, patients with significant congenital
anomalies at birth (congenital heart disease, gastroschisis, omphalocele, intestinal atresia, hydrocephalus, etc.) or
patients involved in another study protocol using WBTH
were excluded. Of note, patients with moribund conditions or
congenital/chromosomal anomalies with poor likelihood of
survival in the neonatal period were not treatment candidates
as per the standard protocol for WBTH at our institution.
2.4. Study Design. We performed a twofold analysis of the
data by comparing infants in the strict criteria group who
received WBTH to those who did not and comparing infants
in the general criteria group who received WBTH to those
who did not. If information was missing in the medical
record for the individual research parameters, the patient
was excluded only from the statistical analysis of that specific
parameter. Primary outcomes were day of life (DOL) enteral
feeds started, DOL full enteral feeds reached, and DOL
full oral feeds reached. Secondary outcomes included never
started enteral feeds, never reached full enteral feeds, never
reached full oral feeds, death, GT, combined death and GT,
discharge with gavage feeds, combined death and discharge
with gavage feeds, NEC, use of extracorporeal membrane

oxygenation (ECMO), elevated liver enzymes, elevated coagulation parameters, and days to hospital discharge or death.
These outcomes were chosen as objective measures of GI
morbidity and feeding tolerance that could be easily determined from the electronic medical documentation. Other
variables such as gastric residuals and withholding of feeds
were considered for outcome measures but were not well
documented in the electronic medical record and could not
be used for this study.
2.5. Statistical Methods. Data are expressed as mean ± standard deviation (SD) for continuous outcome variables and
percentage for categorical outcome variables. Characteristics
of WBTH and non-WBTH patients were compared using
Chi-square test, Fisher’s exact test, and 𝑡-test. Patients who
did not start or reach full enteral feeds due to death were
treated as censored data. Patients who did not reach full
oral feeds due to death, GT placement, or discharge with
gavage feeds were also treated as censored data. Kaplan-Meier
survival curves were generated for WBTH and non-WBTH
patients. We then performed the log-rank test to compare
survival curves between the two groups. All analyses were
performed using SAS 9.2 (Cary, NC) and SPSS 20. Statistical
significance was claimed at 95% confidence level (𝑃 < 0.05).

3. Results
3.1. Comparison of Demographic Data. Overall, there were
more males (59% of total study population) than females and
more Caesarean sections performed (66% of total study population) than vaginal deliveries for infants with moderateto-severe HIE. There were slight differences in birth weight,
gestational age, and maternal age between the groups, but
we do not feel that these differences affected our results. The
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Table 1: Demographics for all subjects.

Variable
General criteria group
Gender (% male)
Birth weight (grams)
Gestational age (weeks)
Maternal age (years)
Cesarean delivery
5-minute APGAR score
Strict criteria group
Gender (% male)
Birth weight (grams)
Gestational age (weeks)
Maternal age (years)
Cesarean delivery
5-minute APGAR score
∗

WBTH
(𝑛 = 70)
44 (63%)
3447.1 ± 524.2
39.0 ± 1.5
25.4 ± 6.3
45 (64%)
3.0 ± 2.1
(𝑛 = 36)
18 (50%)
3510 ± 523.7
39.2 ± 1.5
25.4 ± 6.9
21 (58%)
4.1 ± 1.8

Non-WBTH
(𝑛 = 78)
44 (56%)
3262.0 ± 570.3
38.4 ± 1.9
29.8 ± 15.6
52 (67%)
3.3 ± 2.0
(𝑛 = 32)
18 (56%)
3120.1 ± 568.6
38.3 ± 1.7
27.9 ± 7.6
23 (72%)
2.2 ± 1.8

𝑃 value
0.50
0.04∗
0.02∗
0.03∗
0.86
0.29
0.63
<0.01∗
0.02∗
0.17
0.31
<0.001∗

Significance defined by 𝑃 < 0.05.

degree of HIE, defined by the 5-minute APGAR score, was
similar for the general criteria group, but the strict WBTH
group had lower APGAR scores at 5 minutes when compared
with the non-WBTH group (2.2±8 versus 4.1±1.8, 𝑃 < 0.001).
However, the mean score was below 5 at 5 minutes for both
groups, suggesting that the groups had comparable degrees of
depression at birth (Table 1).
3.2. Comparison between WBTH (𝑛 = 36) and Non-WBTH
(𝑛 = 32) Using Strict Criteria. The non-WBTH group had
more infants who never started on enteral feeds due to death
(28% versus 6%, 𝑃 = 0.02), more infants who never reached
full enteral feeds due to death (38% versus 6%, 𝑃 = 0.002),
and more infants who never reached full oral feeds due to
death, GT placement, or discharge with gavage feeds (56%
versus 19%, 𝑃 = 0.002) as compared to the WBTH group.
The non-WBTH group has a higher mortality rate than the
WBTH group (32% versus 6%, OR (95% CI): 7.9 (1.6–39.5),
𝑃 = 0.009). The non-WBTH group had a higher rate of
combined death and GT placement (46.9% versus 11.1%, 𝑃 =
0.001) and combined death and gavage feeds at discharge
(43.8 versus 11.1, 𝑃 = 0.005). Survival analysis was performed
to take the censoring into account. The Kaplan Meier curves
demonstrated that infants in the WBTH group reached full
enteral feeds (median time: 11 versus 9 days, 𝑃 = 0.02) and
full oral feeds (median time: 19 versus 10 days, 𝑃 = 0.01)
sooner than those in the non-WBTH group (Figure 2). There
were only 3 cases of NEC, but they were all in the non-WBTH
group (9% versus 0%, 𝑃 = 0.1) There was no difference in
elevation of liver enzymes (63% versus 63.9%, 𝑃 = 0.94) or
abnormal coagulation factors (91.3% versus 100%, 𝑃 = 0.15)
between groups (Table 2).
3.3. Comparison between WBTH (𝑛 = 70) and Non-WBTH
(𝑛 = 78) Using General Criteria. There was no statistical
significance between groups for primary outcomes, mortality,
or GI morbidity measures. There were few cases of NEC, and
there was no statistical significance of occurrence of NEC

between groups (5% versus 3%, 𝑃 = 0.68). However, there
were an increased number of infants who never reached full
oral feeds due to death, GT placement, or discharge with
gavage feeds in the non-WBTH group versus the WBTH
group (42% versus 26%, 𝑃 = 0.03). Also, infants who received
WBTH had elevated coagulation parameters (prothrombin
time > 15.6 seconds and partial thromboplastin time > 41.5
seconds) (80% versus 100%, 𝑃 = 0.0001) more often than
those not treated with WBTH, but there was no difference
in the number of infants with elevated liver enzymes between
groups (54.6% versus 62.9%, 𝑃 = 0.33) (Table 3).

4. Discussion
Our analysis suggests that infants treated with WBTH for
moderate-to-severe HIE may have improved feeding tolerance, GI morbidity, and overall mortality compared with
those not treated with WBTH. Infants treated with WBTH
strict criteria group reached full enteral feeds and full oral
feeds sooner than those not treated. The WBTH strict criteria
group had a lower overall mortality as well as combined
GI morbidity (defined as GT placement or gavage feeds at
discharge) and mortality.
Our results show that the majority of subjects had
elevated liver enzymes and elevated coagulation parameters,
expected sequelae of HIE [15, 16]. Other studies have reported
that these effects were only temporary with improvement
in liver enzymes and coagulation parameters over time, and
our results were consistent (data not shown). There was,
however, no significant difference in the number of infants
with elevated liver enzymes between the WBTH and nonWBTH groups in our study.
Interestingly, there was no difference in the DOL feeds
initiated between groups in either analysis. This retrospective study covered a wide time frame during which many
changes occurred in medical practice, including the standard
use of WBTH for moderate-to-severe HIE and the use of
standardized feeding protocols. The feeding protocols are
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Table 2: Primary and secondary outcome variables for strict criteria group.
Variable

DOL enteral feeds started
DOL full enteral feeds reached
DOL full oral feeds reached
Never started enteral feeds
Never reached full enteral feeds
Never reached full oral feeds
Death
GT
Combined death and GT
Discharged with gavage feeds
Combined death and discharged with gavage feeds
NEC+
ECMO
Elevated liver enzymes†
Elevated coagulation parameters∞
Days to hospital discharge or death
∗

WBTH
(𝑛 = 36)
Primary outcomes (mean ± SD)
5.6 ± 2
10.1 ± 3.7
11.5 ± 5.6
Secondary outcomes (%)
5.6
5.6
19.4
5.7
5.6
11.1
5.6
11.1
0
8.3
63.9
100
16.9 ± 11.1

Non-WBTH
(𝑛 = 32)

𝑃 value

6±3
11.3 ± 5.6
12.7 ± 6.7

0.12
0.02∗
0.01∗

28.1
37.5
56.3
32.3
15.6
46.9
9.4
43.8
9.4
0
63
91.3
16.9 ± 12

0.02∗
0.002∗
0.002∗
0.009∗
0.24
0.001∗
0.66
0.005∗
0.1
0.24
0.94
0.15
1

Significance defined by P < 0.05.
Grossly bloody stool (Bell’s stage IIA or greater).
†
Aspartate aminotransferase level >200 IU and alanine aminotransferase level >100 IU.
∞
Prothrombin time >15.6 seconds and partial thromboplastin time >41.5 seconds.
+

Table 3: Primary and secondary outcome variables for general criteria group.
Variable

DOL enteral feeds started
DOL full enteral feeds reached
DOL full oral feeds reached
Never started enteral feeds
Never reached full enteral feeds
Never reached full oral feeds
Death
GT
Combined death and GT
Discharged with gavage feeds
Combined death and discharged with gavage feeds
NEC+
ECMO
Elevated liver enzymes†
Elevated coagulation parameters∞
Days to hospital discharge or death
∗

WBTH
(𝑛 = 70)
Primary outcomes (mean ± SD)
5.4 ± 2.2
9.9 ± 4.3
11.4 ± 6.2
Secondary outcomes (%)
12.9
12.9
25.7
15.9
10
26
2.9
17.4
2.9
5.7
62.9
100
15.8 ± 10.2

Significance defined by P < 0.05.
Grossly bloody stool (Bell’s stage IIA or greater).
†
Aspartate aminotransferase level >200 IU and alanine aminotransferase level >100 IU.
∞
Prothrombin time >15.6 seconds and partial thromboplastin time >41.5 seconds.
+

Non-WBTH
(𝑛 = 78)

𝑃 value

5.8 ± 2.6
10.4 ± 6.1
11.4 ± 6.9

0.39
0.12
0.13

21.8
25.6
42.3
23.4
12.8
36.4
7.7
31.2
5.1
1.3
54.6
80.4
16.2 ± 10.9

0.15
0.05
0.03∗
0.26
0.29
0.21
0.28
0.06
0.68
0.19
0.33
0.0001∗
0.83
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Figure 2: Survival curves for subjects with strict criteria∗ . ∗ Censored subjects are labeled.

primarily used for the initiation and advancement of feeds
in preterm infants. There is no current standardized practice
for initiating feeds in late-preterm and term infants with HIE
at our institution. However, we expected to see a difference in
practice for initiation of feeds over the twelve-year timeframe
of our study, believing that many providers would feel more
comfortable starting feeds sooner in the group of infants
treated with WBTH. Since this was not the case, our results
are actually strengthened by the fact that both groups were
fed similarly.
Limitations of the study include the small sample size
and retrospective analysis of data. A historical cohort study
was performed because therapeutic hypothermia has been
accepted as the standard of care for infants with moderate-tosevere HIE; a prospective analysis or randomized controlled
trial is not an ethical option to evaluate the effects of WBTH
on GI morbidity and feeding following a perinatal hypoxic
event. We estimate that fewer infants with HIE were referred
to our tertiary care institution prior to use of WBTH due to
the lack of therapeutic options, further limiting the number
of patients available for analysis. The study was also limited
by the quality of documentation in the medical record. This
was the reason for dividing the groups into strict and general
criteria based on the level of documentation available. When
there was a lack of adequate information, the research team
either determined an infant that met criteria for moderateto-severe HIE based on other findings in the medical record
(such as multiple abnormal lab values or even death) or
decided to exclude the infant from the study if insufficient
evidence was found. Although the 5 minute APGAR score
was lower in the non-WBTH strict group versus the WBTH
strict group, both groups had a mean score <5 at 5 minutes of
life to suggest a considerable level of depression after birth in
each one. The lower mortality seen specifically in the WBTH
strict criteria group may arguably be explained by the fact that
these infants were already a subgroup of infants with more

significant illness. However, the lower mortality combined
with more significant results seen in the groups of infants with
clear evidence of moderate-to-severe HIE by a more strict
definition validates the strict use of cooling criteria used by
our institution.
It should be noted that a requirement for GT placement
or gavage feeds at discharge or the number of days to reach
full oral feeds could all be reflections of oral skills. Those
differences seen in our study could arguably be similar to
the known improvements in neurologic function seen with
WBTH. However, advancement of enteral feeds is a more
specific measure of GI motility and the decreased number
of days to reach full enteral feeds alone suggests a nonneural
benefit to WBTH.
Future implications for study may include use of therapeutic hypothermia for other causes of gastrointestinal
ischemia-reperfusion injury such as NEC. NEC is a unique
form of gastrointestinal ischemia that occurs most often in
preterm infants. Its exact etiology is not fully elucidated and
felt to be multifactorial. In 2010, Hall et al. [17] published
a small randomized prospective pilot study establishing the
safety of using WBTH in preterm infants with advanced stage
surgical NEC. The authors of the study plan to complete
a larger multicenter randomized controlled trial evaluating
the use of therapeutic hypothermia to decrease the amount
of GI ischemic injury and surgical intervention required for
NEC. Although our study was not powered for the incidence
of NEC, we see interesting trends in the small numbers of
patients with NEC and moderate-to-severe HIE. Our study
strongly supports the need for further research in this area.
Next steps could include a larger, multicentered cohort study
evaluating the incidence of NEC in infants with HIE before
and after the use of WBTH.
In conclusion, WBTH use for moderate-to-severe HIE
may have beneficial effects to the newborn that extend
beyond neurocognitive and neurodevelopmental outcomes.
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Our findings suggest that WBTH improves GI morbidity and
feeding tolerance for infants with moderate-to-severe HIE
when strict criteria for cooling are applied.
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